Patent Grant
10046093
Embodiments of the present invention relate to the field of medical therapeutic agent delivery. More particularly embodiments of this invention relate to methods and devices used for local delivery of water-soluble or water-insoluble therapeutic agents to the surface of normal or diseased body lumens.
Sporadic, inherited, environmental, and iatrogenic diseases associated with significant morbidity and mortality develop in the wall of endothelial cell-lined and epithelial cell-lined body lumens. For example, atherosclerosis and post-procedural restenosis develop in the arterial wall. Adenocarcinoma, esophageal varices, and cholangiocarcinoma develop in the gastrointestinal tract wall. The efficacy of systemic drug therapy for these diseases may be limited by inadequate drug delivery to the diseased tissue and/or dose limiting toxic effects in non-diseased tissue. Local delivery of drugs to diseased tissue in body lumen walls can overcome these limitations: therapeutic concentrations of drugs can be achieved without systemic toxicity.
Embodiments of the present invention disclose a novel approach to coating an expandable structure of a medical disposable device, such as a balloon of a balloon catheter, which can be used for local therapeutic agent delivery to the surface of body lumens. The approach permits forming a coating with high levels of a therapeutic agent (e.g. paclitaxel) and utilizes a unique chemical formulation designed to permit forming a coating that provides a uniform therapeutic agent density across the balloon surface using a simple, reproducible and hence easily manufacturable application process. This novel coating process can be used to locally delivery a uniform dose of water-soluble and water-insoluble therapeutic agents to treat a variety of diseases that arise in body lumen walls. In addition, the novel coating approach may accommodate therapeutic levels of combinations of therapeutic agents (e.g. paclitaxel and dexamethasone acetate) directed at distinct therapeutic targets to increase the therapeutic efficiency of the procedure.
In an embodiment, a coating solution is single-dip coated on an expandable structure having an outer surface, such as an angioplasty balloon useful for either coronary or peripheral arteries, in order to form an amphiphilic polymer coating on the outer surface of the expandable structure. The coating solution contains an amphiphilic polymer or co-polymer in majority or exclusively non-aqueous solvents, a therapeutic agent or combination of therapeutic agents (e.g. paclitaxel and dexamethasone acetate), and an optional plasticizer and/or wax. In an embodiment, the amphiphilic polymer or co-polymer is complexed with iodine, which is not covalently bound to the amphiphilic polymer or co-polymer. The coating solution may also contain a plurality of amphiphilic polymers or co-polymers. After coating, the balloon is dried and folded for delivery.
The coated medical disposable device may then be used in a therapeutic operation. In an embodiment, the coated medical disposable device is inserted into a body lumen and expanded to contact the amphiphilic polymer coating against the body lumen. Hydration of the coating occurs immediately when exposed to aqueous fluids, such as blood in vivo, causing the amphiphilic polymer coating to dissolve and the therapeutic agent to release into tissue of the body lumen. The total solubility of the amphiphilic polymer or co-polymer in blood prevents any embolic hazard associated with the amphiphilic polymer coating. Thus, the amphiphilic polymer coating is bioerodable, and non-durable. In an embodiment, at least 90% of the amphiphilic polymer coating is dissolved within 300 seconds of inflating, and more preferably with 90 seconds of inflating. Also, this active dissolution of the amphiphilic polymer coating assists the transfer of hydrophobic, water-insoluble therapeutic agents such as paclitaxel from the balloon to the tissue.
In accordance with embodiments of the invention, the amphiphilic polymer or co-polymer may be complexed with iodine. It is demonstrated that complexed iodine increases the solubility of water-insoluble therapeutic agents such as paclitaxel, rapamycin and everolimus in aqueous conditions. This suggests that the complexed iodine may additionally assist in tissue uptake of the water-insoluble therapeutic agents in vivo. In an embodiment, the dried amphiphilic polymer coating includes a therapeutic agent dispersed in a polymer matrix comprising at least one amphiphilic polymer or co-polymer complexed with iodine, an optional plasticizer and/or wax. In an embodiment, the dried amphiphilic polymer coating comprises at least one amphiphilic polymer or co-polymer complexed with iodine and at least one amphiphilic polymer or co-polymer which is not complexed with iodine. In an embodiment, 25-100 wt % of the total amphiphilic polymer or co-polymer in the dried coating is complexed with iodine. For example, the dried coating may contain 0-75 wt % of an amphiphilic polymer which is not complexable with iodine and 25-100 wt % iodinated PVP as amphiphilic polymer components.
In an embodiment, the dried coating present on the balloon has an iodine to iodine complexable amphiphilic polymer and/or co-polymer weight ratio (I/P) of 1-30%, a therapeutic agent (drug) to polymer matrix weight ratio (D/P) from 25-100%, and a drug density of approximately 0.1-10.0 μg/mm2. In an embodiment, the dried coating is present on a catheter balloon, the drug is paclitaxel, and the amphiphilic polymer is PVP. The dried coating has an iodine to PVP weight ratio (I/P) of 1-30%, a paclitaxel to polymer matrix weight ratio (D/P) from 25-100%, and a paclitaxel density of approximately 0.1-5.0 μg/mm2.
Embodiments of the present invention disclose methods and devices used for local delivery of water-soluble or water-insoluble therapeutic agents to the surface of normal or diseased body lumens.
Various embodiments described herein are described with reference to figures. However, certain embodiments may be practiced without one or more of these specific details, or in combination with other known methods and configurations. In the following description, numerous specific details are set forth, such as specific configurations, compositions, and processes, etc., in order to provide a thorough understanding of the present invention. In other instances, well-known processes and manufacturing techniques have not been described in particular detail in order to not unnecessarily obscure the present invention. Reference throughout this specification to “one embodiment” or “an embodiment” means that a particular feature, configuration, composition, or characteristic described in connection with the embodiment is included in at least one embodiment of the invention. Thus, the appearances of the phrase “in one embodiment” or “an embodiment” in various places throughout this specification are not necessarily referring to the same embodiment of the invention. Furthermore, the particular features, configurations, compositions, or characteristics may be combined in any suitable manner in one or more embodiments.
In one aspect, embodiments of the invention disclose a medical disposable device in which an amphiphilic polymer coating is disposed on the outer surface of an expandable structure. The amphiphilic polymer coating includes at least one therapeutic agent and at least one amphiphilic polymer or co-polymer. The amphiphilic polymer coating may optionally include additional components such as a plasticizer and/or wax. The therapeutic agent can be either water-soluble or water-insoluble. Hydration of the amphiphilic polymer coating occurs immediately when exposed to aqueous fluids such as blood in vivo causing the amphiphilic polymer coating to dissolve and the therapeutic agent to release into tissue of the body lumen. The total solubility of the polymer or co-polymer in blood prevents any embolic hazard associated with the amphiphilic polymer coating.
In an embodiment, the medical disposable device is a catheter with an expandable balloon having an amphiphilic polymer coating comprising a therapeutic agent. The catheter is advanced within a body lumen to align the balloon with the target tissue, the balloon is expanded to 2-20 atmospheres to bring the amphiphilic polymer coating into contact with the target tissue, causing the amphiphilic polymer coating to dissolve and the therapeutic agent payload to release rapidly to the target tissue in vivo because the device will contact the target tissue for only a short amount of time, approximately 5 to 300 seconds. Because the device is to be used for only a short time period and then removed from the body, it is considered to be a “medical disposable” device rather than “implantable.”
The term amphiphilic as used herein means dissolvable in aqueous solvents such as, but not limited to, blood in-vivo, as well as in non-aqueous solvents such as, but not limited to, ethanol, methanol, and/or isopropanol. Accordingly, an “amphiphilic polymer coating” and “amphiphilic polymer or co-polymer” according to embodiments of the invention are dissolvable in both aqueous and non-aqueous solvents. It is to be appreciated that while all components included in the amphiphilic polymer coating may not necessarily be dissolvable in both aqueous and non-aqueous solvents, that the aggregate polymer matrix of the amphiphilic polymer coating is dissolvable in both aqueous and non-aqueous solvents. For example, embodiments of the invention may utilize water-soluble and/or water-insoluble therapeutic agents, as well as a water-insoluble wax or small minority of a hydrophobic polymer or co-polymer, for example, interdispersed in the aggregate polymer matrix of the amphiphilic polymer coating. For example, a small minority of hydrophobic polymer or co-polymer could be added to extend the lifetime of the coating in vivo or slightly retard the release rate of the therapeutic agent, while still allowing rapid and uniform dissolution of the coating in vivo. While an individual component or components of the amphiphilic polymer coating may not be dissolvable in both aqueous and non-aqueous solvents, the continuous aggregate polymer matrix may nevertheless be uniformly dissolved and removed from a substrate in both aqueous and non-aqueous solvents. Accordingly, the term amphiphilic polymer coating is understood to mean that the aggregate polymer matrix of the coating is uniformly dissolvable and removable from a substrate in both aqueous and non-aqueous solvents.
Amphiphilic Polymers or Co-polymers
In one aspect, embodiments of the invention disclose an amphiphilic polymer coating including one or more amphiphilic polymers or co-polymers. In an embodiment, the amphiphilic polymer or co-copolymer is a non-ionic thermoplastic polymer or co-polymer. In an embodiment, the amphiphilic polymer is hydroxypropyl cellulose (HPC) or polyvinyl pyrrolidone (PVP). In an embodiment, the amphiphilic polymer or co-copolymer is complexed with iodine and the iodine is not covalently bonded to the amphiphilic polymer or co-copolymer. For example, PVP and HPC may be complexed with iodine. PVP complexed with iodine is also known as povidone iodine. Surprisingly, as suggested by the results of Table I, complexing a non-ionic amphiphilic polymer with iodine may increase solubility of a water-insoluble therapeutic agent such as paclitaxel, rapamycin and everolimus in vivo and therefore assist in tissue uptake of the water-insoluble therapeutic agent. This can reduce the time requirements of the medical procedure and amount of mechanical pressure and/or metabolic insufficiencies caused by sustained inflation of the expandable structure. In an embodiment, the amount of iodine complexed with the iodine complexable amphiphilic polymer and/or co-polymer in the coating is 1 to 30 weight % of the dry iodine complexable amphiphilic polymer and/or co-polymer weight.
In an embodiment, the dried coating comprises at least one amphiphilic polymer or co-polymer complexed with iodine and at least one amphiphilic polymer or co-polymer which is not complexed with iodine. In an embodiment, 25-100 wt % of the total amphiphilic polymer or co-polymers in the dried coating are complexed with iodine. For example, 25-100 wt % of the total amphiphilic polymer and/or co-polymer in the polymer matrix may be povidone iodine.
Complexing with iodine can also serve addition functions. It imparts an amber hue on the amphiphilic polymer coating, aiding in visualization outside of the body, and with the coating process. Additionally, as iodine has a large nuclear radius, it will provide radiopacity under fluoroscopy; the expandable structure will be visible under fluoro, and the dissolution of the amphiphilic polymer coating can be monitored as a function of time.
In an embodiment, the amphiphilic polymer or co-polymer is an ionic thermoplastic co-polymer or co-copolymer. For example, the amphiphilic polymer or co-copolymer can be poly (methyl vinyl ether-alt-maleic acid monobutyl ester) (available under the trade name Gantrez ES-425, from International Specialty Products (ISP), Wayne, N.J.) or poly (methyl vinyl ether-alt-maleic acid monoethyl ester) (available under the trade name Gantrez ES-225, from International Specialty Products (ISP), Wayne, N.J.).
HPC (non-iodinated), iodinated HPC, iodinated PVP (povidone iodine), poly (methyl vinyl ether-alt-maleic acid monobutyl ester), and poly (methyl vinyl ether-alt-maleic acid monoethyl ester) are soluble in lower alcohols without the use of any water, which provides for a low surface tension and rapid evaporation. As used herein, the term “lower alcohols” means an alcohol having 4 carbon atoms or less. They are also freely soluble in water resulting in rapid dissolution in vivo. In an embodiment, this is beneficial when it is desired that the therapeutic agent transfer take place within 90 to 300 seconds of inflation. When the above amphiphilic polymers or co-polymers are dissolved in sufficient ethanol, alone or in combination, they are also freely miscible with acetone. In an embodiment, where the therapeutic agent includes paclitaxel, this can be beneficial because paclitaxel is highly soluble in a mixture of a lower alcohol (e.g. ethanol, 2-propanol, n-butanol) and warm acetone, and the solvent combination enables a high drug loading. In another embodiment, the polymer or co-polymer may not be fully amphiphilic. For example, hydroxypropyl methyl cellulose is not fully soluble in non-aqueous solvent, however some grades are soluble in a solution which contains approximately 10% water and 90% non-aqueous solvent.
In an embodiment, the amphiphilic polymer coating may optionally include a plasticizer in the polymer matrix. A plasticizer may be particularly useful to increase the ductility and prevent the coating from cracking or delaminating while bending or folding in the dry state. Suitable plasticizers include, but are not limited to, polyethylene glycol (PEG) with a molecular weight below 10 K Daltons, propylene glycol, triethyl citrate, glycerol, and dibutyl sebacate. In an embodiment, the plasticizer is PEG-400. In an embodiment, the amphiphilic polymer is PVP-based (iodinated or non-iodinated) and the plasticizer is present at 30% to 85% by weight of the PVP. In an embodiment, the amphiphilic polymer is HPC-based (iodinated or non-iodinated) and the plasticizer is present at 5% to 15% by weight of the HPC.
In an embodiment, the amphiphilic polymer coating may optionally include a wax in the polymer matrix. A wax-like surface assists with the gliding quality of the amphiphilic polymer coating in relation with a body lumen surface and/or in relation with an optional protective sheath over the amphiphilic polymer coating. Suitable waxes include, but are not limited to bees wax, carnauba wax, polypropylene glycol, polydimethyl siloxane (PDMS), and PDMS derivatives.
In an embodiment, the amphiphilic polymer coating may optionally include a small minority of hydrophobic polymer or co-polymer in the polymer matrix to slightly extend the lifetime of the coating in vivo or slightly retard the release rate of the therapeutic agent, while still allowing rapid and uniform dissolution of the coating in vivo.
Therapeutic Agents
In another aspect, embodiments of the invention disclose an apparatus and method for delivering therapeutic agents to treat a variety of diseases that arise in body lumen walls. The therapeutic agents useful in accordance with the present invention may be used singly or in combination. The therapeutic agents may be non-aqueous soluble (i.e. solvent soluble) and/or aqueous soluble. In an embodiment, the dried coating has a therapeutic agent (drug) to polymer matrix weight ratio (D/P) from 25-100%. As used herein the D in the D/P ratio includes all of the drugs in the coating unless the D/P ratio is utilized differently to specifically represent a single drug in the coating. The D/P may depend upon the molecular weight of the amphiphilic polymer and/or co-polymer, and presence of additional components such as a plasticizer and/or wax. D/P ratios higher than 100% may result longer dissolution times in vivo, thereby providing less efficient drug delivery during a treatment operation where a delivery balloon is inflated for 300 seconds or less. Additionally, D/P ratios higher than 100% may increase the likelihood of particulate generation, particularly for water-insoluble drugs. D/P ratios below 25% may require excessive coating thickness to achieve the required therapeutic agent loading on the medical disposable device. In an embodiment, the D/P ratio is 35-60%.
In an embodiment, the dried coating has a therapeutic agent (drug) density of approximately 0.1-10.0 μg/mm2. The drug density may vary depending upon factors such as the specific drug and polymer matrix selections. In an embodiment, the dried coating is present on a catheter balloon, the drug is paclitaxel, and the amphiphilic polymer is PVP, and the dried coating has a paclitaxel density of approximately 0.1-3.0 μg/mm2.
In an embodiment, non-aqueous soluble therapeutic agents are particularly useful as components in a coating composition which includes a majority or exclusively non-aqueous solvents. For example, a non-aqueous soluble anti-proliferative agent such as paclitaxel may be used in combination with another therapeutic agent such as the anti-inflammatory agent dexamethasone. In an embodiment, therapeutic agents which may be, singly or in combination, locally delivered to the surface of normal or diseased body lumens can be classified into the categories of anti-proliferative agents, anti-platelet agents, anti-inflammatory agents, anti-thrombotic agents, and thrombolytic agents. These classes can be further sub-divided. For example, anti-proliferative agents can be anti-mitotic. Anti-mitotic agents inhibit or affect cell division, whereby processes normally involved in cell division do not take place. One sub-class of anti-mitotic agents includes vinca alkaloids. Representative examples of non-aqueous soluble vinca alkaloids include, but are not limited to, paclitaxel (including the alkaloid itself and naturally occurring forms and derivatives thereof, as well as synthetic and semi-synthetic forms thereof), vincristine, etoposide, indirubin, and anthracycline derivatives, such as, for example, daunorubicin, daunomycin, and plicamycin. Other sub-classes of anti-mitotic agents include anti-mitotic alkylating agents, such as, for example non-aqueous soluble fotemustine, and anti-mitotic metabolites, such as, for example, non-aqueous soluble azathioprine, mycophenolic acid, leflunomide, teriflunomide, fluorouracil, and cytarabine. Anti-mitotic alkylating agents affect cell division by covalently modifying DNA, RNA, or proteins, thereby inhibiting DNA replication, RNA transcription, RNA translation, protein synthesis, or combinations of the foregoing.
Examples of non-aqueous soluble anti-inflammatory agents that can also be used include, but are not limited to, dexamethasone, prednisone, hydrocortisone, estradiol, triamcinolone, mometasone, fluticasone, clobetasol, and non-steroidal anti-inflammatories, such as, for example, acetaminophen, ibuprofen, and sulindac. The arachidonate metabolite prostacyclin or prostacyclin analogs are examples of a vasoactive antiproliferative.
Therapeutic agents with pleiotropic effects on cell proliferation, immunomodulation and inflammation may also be used. Examples of such non-aqueous soluble agents include, but are not limited to the macrolides and derivatives thereof such as sirolimus (e.g. rapamycin), tacrolimus, everolimus, temsirolimus.
Anti-platelet agents are therapeutic entities that act by (1) inhibiting adhesion of platelets to a surface, typically a thrombogenic surface, (2) inhibiting aggregation of platelets, (3) inhibiting activation of platelets, or (4) combinations of the foregoing. Non-aqueous soluble anti-platelet agents that act as inhibitors of adhesion of platelets include, but are not limited to, and tirofiban and RGD (Arg-Gly-Asp)-based peptides (Pegylated) that inhibit binding to gpIIbIIIa or .alpha.v.beta.3, compounds that block P-selectin or E-selectin binding to their respective ligands. Agents that inhibit ADP-mediated platelet aggregation include, but are not limited to, cilostazol.
Anti-thrombotic agents include chemical and biological entities that can intervene at any stage in the coagulation pathway. Examples of specific non-aqueous soluble entities include, but are not limited to, small molecules that inhibit the activity of factor Xa. Also included are direct thrombin inhibitors, such as, for example, argatroban, inogatran.
Other non-aqueous soluble therapeutic agents that can be used are cytotoxic drugs, such as, for example, apoptosis inducers, and topoisomerase inhibitors, including, irinotecan, and doxorubicin, and drugs that modulate cell differentiation such as inhibitors of histone deacetylase, including valproic acid.
Other non-aqueous soluble therapeutic agents that can be used include anti-lipaedemic agents, including but not limited to fenofibrate, clofibrate, and rosiglitazone and matrix metalloproteinase inhibitors, such as, for example, batimistat, antagonists of the endothelin-A receptor, such as, for example, darusentan.
In another embodiment, aqueous soluble therapeutic agents may be used. Aqueous soluble anti-mitotic agents include Epothilone A, Epothilone B and Epothilone D, and all other Epothilones. Aqueous soluble anti-platelet agents include RGD (Arg-Gly-Asp)-based peptides that inhibit binding to gpIIbIIIa or .alpha.v.beta.3. Aqueous soluble anti-thrombotic agents include heparinoid-type agents that can inhibit both FXa and thrombin, either directly or indirectly, such as, for example, heparin, heparin sulfate, low molecular weight heparins, such as, for example, the compound having the trademark Clivarin®, and synthetic oligosaccharides, such as, for example, the compound having the trademark Arixtra®. Aqueous soluble thrombolytic agents, which may be defined as agents that help degrade thrombi (clots), can also be used as adjunctive agents, because the action of lysing a clot helps to disperse platelets trapped within the fibrin matrix of a thrombus. Representative examples of thrombolytic agents include, but are not limited to, urokinase or recombinant urokinase, pro-urokinase or recombinant pro-urokinase, tissue plasminogen activator or its recombinant form, and streptokinase. Additional aqueous soluble therapeutic agents include recombinant antibodies for anti-platelet and anti-endothelin applications.
When used in the above or other treatments, a therapeutically effective amount of one of the non-aqueous soluble or aqueous soluble therapeutic agents in embodiments of the invention may be employed in pure form or, where such forms exist, in pharmaceutically acceptable salt, ester or prodrug form. Alternatively, the therapeutic agent may be administered as a pharmaceutical composition including the compound of interest in combination with one or more pharmaceutically acceptable excipients. As used herein, the phrase “therapeutically effective amount” of the therapeutic agents of the invention means a sufficient amount of the therapeutic agents to treat disorders, at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the therapeutic agents and compositions of embodiments of the invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts. For example, it is well within the skill of the art to start doses of the therapeutic agent at levels lower than required to achieve the desired therapeutic effect and to gradually increase the dosage until the desired effect is achieved.
Coating Process
The amphiphilic polymer coating containing a therapeutic agent or agents and an amphiphilic polymer or co-polymer can be formed from with a variety of techniques including deposition, spray coating, and dip coating.
In an embodiment, the coating solution 114 viscosity is at least 5 cps and less than approximately 75 cps. After dipping the expanded balloon 112 into the coating solution 114, the expanded balloon 112 is then removed from the coating solution, as shown in
In an embodiment, the use of an amphiphilic polymer or co-polymer and non-aqueous soluble therapeutic agent enables the use of non-aqueous solvents to dissolve the polymer or co-polymer and therapeutic agent. In alternate embodiments, where the therapeutic agent is not soluble in non-aqueous solutions, an aqueous solution may be used. A majority or exclusively non-aqueous solvents in the coating solution provides rapid evaporation, a lower surface tension, and improved substrate wetting compared to an aqueous solution, which aids in obtaining coating uniformity. For example, solvents with boiling points lower than water can be used singly or in combination in the coating solution 114, such as ethanol, methanol, or methyl ethyl ketone, isopropanol (2-propanol), and/or butanol that rapidly evaporate in ambient conditions, which consequently reduces gravity induced surface defects such as sagging. Dip coating into a coating solution with majority or exclusively non-aqueous solvents permits forming a coating with high levels of a therapeutic agent, and permits forming a coating that provides a uniform therapeutic agent density across the balloon surface using a simple, reproducible and hence easily manufacturable application process. For example, when HPC (non-iodinated), iodinated HPC, iodinated PVP (povidone iodine), poly (methyl vinyl ether-alt-maleic acid monobutyl ester), and poly (methyl vinyl ether-alt-maleic acid monoethyl ester) are dissolved in sufficient ethanol, they are also freely miscible with acetone. In an embodiment, where the therapeutic agent includes paclitaxel, this can be beneficial because paclitaxel is highly soluble in a mixture of a lower alcohol (e.g. ethanol, 2-propanol, n-butanol) and acetone, and the solvent combination enables a high drug loading. In an embodiment, the therapeutic agent is rapamycin or everolimus.
The coating solution 114 may be prepared by mixing the therapeutic agent, solvent(s), polymers and other components such as plasticizer into a single container. Several mixing and/or dissolving operations may be also performed prior to combining multiple solutions to form the coating solution 114. For example, where an amphiphilic polymer or co-polymer is complexed with iodine, a complexed polymer solution may be prepared. For example, I2 may be dissolved in alcohol, then dry polymer powder is added to the I2 and alcohol. Agitation and/or heat may be applied to the solution to dissolve the polymer. For example, 0.05 grams of I2 is dissolved in 12 grams of 2-propanol. Then 1.00 grams of PVP (360 KD, ISP) is added. The suspension is shaken continuously until the PVP is dissolved, about 1 hour. In an embodiment, the resulting solution is a 20% povidone-iodine in 2-propanol solution.
The therapeutic agent can then be dissolved in a separate alcohol, or alcohol and acetone solution. For example, 0.1 grams paclitaxel is dissolved in 0.1 grams ethanol and 0.18 grams of 50% PEG-400 in acetone at 40° C. This solution can then be cooled to room temperature and added to 0.55 grams of the 20% povidone-iodine in 2-propanol solution. In an embodiment, the combined coating solution has a drug (i.e. paclitaxel) to polymer matrix (i.e. iodinated-PVP and PEG-400) ratio (D/P) of 50%, the solution is 31.8% non-volatile, and the drug (i.e. paclitaxel) is 33% of the non-volatile.
After coating, the balloon is dried, deflated and folded for delivery. In an embodiment, after the balloon is dried, but before deflating and folding for delivery, the balloon may optionally be dip coated into a separate coating solution containing a wax to form a thin wax coating (not shown) over the amphiphilic polymer coating, rather than incorporating the wax into the amphiphilic polymer coating.
Local Therapeutic Agent Delivery Process
As shown in
In clinical use for angioplasty, it may be preferable for the balloon 212 to be expanded for only 5 to 300 seconds. This time limitation is a due to the type of medical procedure because a longer use time with the balloon inflated could result in the focal or adjacent tissue damage that is deleterious to the therapeutic intent of the procedure. This damage could result from mechanical pressure and/or metabolic insufficiency caused by sustained inflation of the balloon including but not limited to tissue architecture, tissue inflammation, cell death, and induction of reactive scarring within the organ. In an embodiment, a coated angioplasty balloon may be tracked to a target lesion using standard techniques, the optional protective sheath is retracted and the angioplasty balloon is inflated against an artery wall. Hydration of the coating occurs immediately and causes the therapeutic agent to release into tissue, the coating polymer or co-polymer to dissolve, and some of the amphiphilic polymer coating to transfer from the balloon to the artery wall. This paving acts as drug reservoir and is transient. The total solubility of the polymer or co-polymer in blood prevents any embolic hazard associated with the coating. Also, this active dissolution of the polymer or co-polymer matrix assists the transfer of hydrophobic therapeutic agents such as paclitaxel from the balloon to the tissue.
Several embodiments of the invention are described below with reference to the following non-limiting Examples regarding coating of PET coupons. Solution percentages provided are by weight.
One (1.0) grams of a 7.5% solution of 60 K Dalton HPC in ethanol is mixed with 0.15 grams of 1% solution of propylene glycol (plasticizer) in acetone, 0.075 grams paclitaxel and 0.08 grams n-butanol. The mixture is heated in a water bath to dissolve the paclitaxel; a clear solution results. When dip coated (single dip) on PET coupons at a dip speed of about 10 inches/minute, and dried at room temperature, there results a slightly milky dry coating. About 3 cm2 of coupon surface is coated per coupon. The average coating density determined by gravimetric analysis is 6 μg/mm2 and the implied paclitaxel density is 3 μg/mm2. The dry coating is sufficiently ductile to withstand a 180 degree bend without cracking or delaminating.
A coupon coated as above is immersed in 3 ml of 37° C. water for 3 minutes with agitation, after which the coupon is removed and the turbid suspension diluted with 9 ml dimethyl sulfoxide (DMSO) to produce a clear solution. Quantitative UV analysis at 260 nm and 280 nm vs. a standard curve shows an 88% recovery. This result demonstrates the rapid dissolution of the amphiphilic polymer coating and drug release in vitro. The in vivo milieu is expected to present serum proteins with a surfactant effect, which will increase the dissolution rate of the drug and coating polymer in vivo.
0.075 grams paclitaxel is mixed with 0.9 grams of a 20% povidone-iodine solution in 2-propanol, 0.06 grams of a 10% propylene glycol solution in 2-propanol and 0.04 grams acetone. When dip coated (single dip) on a PET coupon at a dip speed of 10 inches/min, and dried at room temperature, there results a clear amber dry coating. About 2.5 μg/mm2 of paclitaxel is deposited.
The above coupon is immersed in 1.5 ml of 37° C. water for 30 seconds. All of the coating dissolves in the water, and the solution is totally transparent amber, and not turbid as in Example 1.
An identical formula to Example 2 is made, however non-iodinated PVP is employed instead of povidone-iodine of the same molecular weight (40 K Dalton). When dip coated (single dip) on a PET coupon at a dip speed of 10 inches/min, and dried at room temperature, there results a clear water white dry coating. About 2.5 μg/mm2 of paclitaxel is deposited.
This coupon is immersed in 1.5 ml of 37° C. water for 30 seconds. All of the coating polymer dissolves in the water, and the solution shows a suspension of needle crystals. This suspension becomes more turbid after 24 hours, while the above amber solution from Example 2 remains transparent. This demonstrates that the povidone-iodine changes the aqueous solubility of paclitaxel.
0.1 grams rapamycin (available from LC Laboratories, Woburn, Mass.) is dissolved in 0.08 grams of a 10% propylene glycol solution in 2-propanol and 0.053 grams acetone at 40° C. The solution is cooled to room temperature, then added to 1.2 grams of a 20% solution of povidone-iodine in 2-propanol. The formula is dip coated (single dip) on a Nylon 12 coupon, and dried at room temperature for 30 minutes. The above coupon is immersed in 1 ml of 37° C. water for one minute. All of the coating dissolves in the water, and the solution is clear amber.
An identical formula to Example 4 is made, however non-iodinated C-30 PVP is employed instead of povidone-iodine. The formula is dip coated (single dip) on a Nylon 12 coupon, and dried at room temperature for 30 minutes. The above coupon is immersed in 1 ml of 37° C. water for one minute. All of the coating dissolves in the water, and the solution is turbid due to the water-insoluble rapamycin.
0.1 grams everolimus (available from LC Laboratories, Woburn, Mass.) is dissolved in 0.08 grams of a 10% propylene glycol solution in 2-propanol and 0.053 grams acetone at 40° C. The solution is cooled to room temperature, then added to 1.2 grams of a 20% solution of povidone-iodine in 2-propanol. The formula is dip coated (single dip) on a Nylon 12 coupon, and dried at room temperature for 30 minutes. The above coupon is immersed in 1 ml of 37° C. water for one minute. All of the coating dissolves in the water, and the solution is clear amber.
An identical formula to Example 6 is made, however non-iodinated C-30 PVP is employed instead of povidone-iodine. The formula is dip coated (single dip) on a Nylon 12 coupon, and dried at room temperature for 30 minutes. The above coupon is immersed in 1 ml of 37° C. water for one minute. All of the coating dissolves in the water, and the solution is turbid due to the water-insoluble everolilmus.
Light scattering experiments at 600 nm and 700 nm were performed comparing the drug (paclitaxel, rapamycin and eyerolimus) and polymer eluted water solutions of Examples 2, 4 and 6 (containing povidone-iodine) with Examples 3, 5 and 7 (containing non-iodinated PVP). The results shown in Table I below provide a quite unexpected increase in solubility of paclitaxel, rapamycin and everolimus in the povidone-iodine eluted water solutions of Examples 2, 4 and 6 compared to the non-iodinated PVP eluted water solution of Examples 3, 5 and 7. Consequently, and quite unexpectedly this suggests that the iodine complexed PVP polymer may assist in tissue uptake of the non-aqueous soluble therapeutic agents in vivo.
Clinical Study
0.1 grams paclitaxel was dissolved in 0.1 grams ethanol and 0.18 grams of 50% PEG-400 in acetone at 45° C. The solution was then cooled to room temperature and added to 0.55 grams of 20% povidone-iodine in 2-propanol. The resulting coating solution contained a D/P ratio of 50%, 31.8 wt % non-volatile components, with the paclitaxel representing 33.3 wt % of the non-volatile components.
Two 2.0×20 over-the-wire balloon catheters (available from ev3 Inc., Plymouth, Minn.) were inflated and cleaned by sonication in 2-propanol for 30 seconds. The catheters were then dried at room temperature and plasma treated for 18 seconds in an argon atmosphere while the balloons were rotated at 0.17 in/min. The balloons were dipped into the resulting coating solution and extracted at a 30 degree angle from horizontal, while rotating the balloon at 30 rpm. When dried, the amount of dried coatings on the balloons was about 1.1-1.2 mg. The first balloon was extracted at 0.17 in/min, resulting in an approximate paclitaxel density of 2.8 μg/mm2 on the balloon surface when dried. The second balloon was extracted at 0.15 in/min, resulting in a drug density of 2.4 μg/mm2 on the balloon surface when dried.
Efficacy of the paclitaxel tissue uptake was tested in vivo in three New Zealand white rabbits. Carotid and femoral arteries were exposed via cut downs, and the catheters were inserted directly into the artery segments, inflated to nominal diameter for 60 seconds, then deflated and removed. The treated artery segments were removed at 40 minutes post deflation and stored immediately on dry ice. Subsequent analysis by liquid chromatography-mass spectrometry (LC/MS) for paclitaxel showed that the average drug concentration in the tissue for the first balloon was 500 μg paclitaxel/gram tissue, and 381 μg paclitaxel/gram tissue for the second balloon. In both instances the amount of average paclitaxel uptake by the tissue was greater than data provided in the SeQuent® Please product brochure number 6050120 (available from B. Braun Vascular Systems, Berlin, Germany) where a tissue concentration of approximately 325 μg paclitaxel/gram tissue was reported in porcine coronary arteries at roughly the same time period (approximately 40 minutes) post deflation in which a paclitaxel drug loading of 3 μg/mm2 in a polymer-free coating was utilized.
Diseases of the Vasculature
One therapeutic area where embodiments of the present invention will be applicable is the treatment of luminal disorders of the vasculature. In general, luminal disorders may be classified as native (atherosclerotic, thromboembolic) or iatrogenic (restenosis) diseases. These luminal disorders may include but not be limited to atherosclerosis, atheromatous lesions, vulnerable plaque, thromboembolic obstructions, vascular graft disease, arteriovenous fistula disease, arteriovenous graft disease and restenosis.
Atherosclerosis is a complex disease of the vessel wall involving the interplay of inflammation, proliferation, lipid deposition and thrombus formation. Atherosclerosis promotes the formation of atheromatous plaques that may progress slowly over several years, leading to progressive obstruction of the vessel lumen manifesting clinically as angina. Atheromatous plaques, may also become “vulnerable plaques” due to an unstable collection of white blood cells (primarily macrophages) and lipids (including cholesterol) in the wall of an artery and become particularly prone to rupture. A rupture of a vulnerable plaque is commonly believed to be the cause of sudden thrombotic obstructions of the vessel lumen due to the rapid formation of blood clots at the rupture site, leading to the clinical manifestations of heart attack or stroke. Vulnerable plaques may not significantly obstruct a vessel lumen until rupture, thus they are pre-obstructive lesions. It is envisioned that a desirable therapeutic target is the prevention of obstruction of the vessel lumen by the treatment of vulnerable plaques prior to their rupture. Specifically, embodiments of the present invention could be applied to a catheter with a tip that is expandable to allow uniform and complete contact with and delivery of therapeutic agents to sites of luminal atheromatous or vulnerable plaques. The local delivery of therapeutic agents would enable a much higher, targeted, local concentration of said agents than might otherwise be achieved by systemic delivery. Moreover, a local delivery strategy would enable the use of therapeutic agents that otherwise may be poor candidates for systemic delivery due to lack of bioavailability and/or undesirable or toxic side effects at concentrations needed to achieve efficacy.
Restenosis
One therapeutic area where embodiments of the present invention will be applicable is inhibiting the process of restenosis. Restenosis is the result of a complex process involving inflammation and proliferation activated by a response to a percutaneous or surgical vascular intervention. Examples of these percutaneous or surgical interventions may include but are not limited to the revascularization of vascular bypass grafts, arteriovenous fistulas, arteriovenous grafts and percutaneous revascularization of coronary, femoral, and carotid vessels. Atherosclerotic plaque arising from the arterial wall can reduce cross-sectional flow area which limits flow to downstream organs. Cross-sectional flow area can be restored by displacing (e.g. expandable balloon or stent) or removing the lesion (e.g. directional or rotational atherectomy). In the months to weeks after revascularization local proliferative of arterial wall smooth muscle cells can create an obstruction to flow at the site of the original atherosclerotic plaque. Paclitaxel is a diterpene molecule containing a complex taxane ring that inhibits cytokinesis by promoting microtubule polymerization. Paclitaxel inhibits smooth muscle cell proliferation and restenosis after balloon angioplasty in a mammalian arteries. Paclitaxel inhibits restenosis after percutaneous coronary revascularization in humans when it is delivered over days to weeks from implanted metal stents that were retained after the revascularization procedure. Brief exposure to paclitaxel (20 minutes of less) can inhibit smooth muscle cell proliferation for sustained periods (14 days). Clinical studies demonstrate that paclitaxel can also effectively inhibit restenosis after femoral and coronary revascularization when it is delivered over a short period (minutes) from an expandable balloon coated with the drug.
Restenosis is a complex molecular process that involves both smooth muscle cell proliferation in addition to inflammatory processes. Dexamethasone is a glucocorticoid that reduces inflammation and restenosis after balloon angioplasty in a mammalian arteries. This suggests that there may be clinical benefit in delivering antimitotic agents such as paclitaxel in combination with anti-inflammatory agents such as dexamethasone from an expandable balloon coated with the two therapeutic agents.
Pulmonary Disease
Another therapeutic area where embodiments of the present invention could be applicable is a luminal surface of normal or diseased airway for the treatment or prevention of focal diseases of the lung and airways. This embodiment may be used in conjunction with both a rigid or flexible bronchoscope which are commonly used to facilitate access to and visualization of the target treatment area.
In general, focal diseases of the airways area neoplasms that are categorized as either benign or malignant. Primary neoplasms may be classified as epithelial, mesenchymal or lymphoid tumors; more than 20 types of tracheal neoplasms have been described.
Carcinoid tumors represent approximately 85 percent of adenomas of the tracheobronchial tree. Adenoid cystic carcinoma is the most frequent adenoma of the trachea. Adenoid cystic carcinoma (or cylindroma) is the second most common malignancy and also the second most common primary tracheal neoplasm.
Conventional treatment for lung cancer can involve surgical removal of tumor, chemotherapy, or radiation therapy, as well as combinations of these methods. The decision about which treatments will be appropriate take into account the localization and extent of the tumor as well as the overall health status of the patient. An example of adjuvant therapy is chemotherapy or radiotherapy administered after surgical removal of a tumor in order to be certain that all tumor cells are killed.
Depending upon the specific neoplasm type and behavior as well as the time of diagnosis, the neoplasm may or may not present a physical obstruction or protrusion into the lumen of the airways. It is envisioned that an approach to restoring functional luminal patency could be to mechanically restore luminal patency by displacing the tumor with a balloon or reduce tumor bulk and then locally delivering a drug to inhibit tumor growth and/or tumor survival. Local drug delivery using embodiments of the present invention could be an effective method of delivering chemotherapeutic agents effective against benign or malignant neoplasms to the luminal aspect of the tumor. Specifically, embodiments of the present invention could be applied to a catheter or a bronchoscope and advanced antegradely or retrogradely to the intended site of local drug delivery. It is envisioned that embodiments of the present invention will enable the local delivery of bioactive (therapeutic) agents to the surface of normal or diseased airway lumens and may be used singly or in combination with surgical removal, chemotherapy and radiation therapy. The local delivery of therapeutic agents would enable a much higher, targeted, local concentration of said agents than might otherwise be achieved by systemic delivery. Moreover, a local delivery strategy would enable the use of therapeutic agents that otherwise may be poor candidates for systemic delivery due to lack of bioavailability and/or undesirable or toxic side effects at concentrations needed to achieve efficacy. The targeted local delivery of therapeutic agents may be used to reduce tumor size to facilitate surgical removal and may eliminate the need for and/or reduce the duration or intensity of systemic chemotherapy or radiotherapy which have numerous unpleasant side effects.
Gastrointestinal Disease
Another therapeutic area where embodiments of the present invention could be applicable is gastrointestinal disease including, but limited to, benign and malignant tumors of the esophagus, biliary tract, colon, and small bowel.
Esophageal tumors are caused by dysregulated division of esophageal smooth muscle or epithelial cells. The tumors can be either benign (e.g. leiomyoma) or malignant (squamous cell carcinoma or adenocarcinoma). These tumors can grow into the lumen and compromise the functional cross-sectional area of the esophagus causing dysphagia (abnormal swallowing) and consequent malnutrition.
It is envisioned that an approach to restoring functional luminal patency could be to mechanically restore luminal patency by displacing the tumor with a balloon or metal dilator or reduce tumor bulk (e.g. laser ablation), and then locally delivering a therapeutic agent to inhibit tumor growth and/or tumor survival. Local therapeutic agent delivery using embodiments of the present invention could be an effective method of delivering chemotherapeutic agents effective against benign or malignant esophageal tumors to the luminal aspect of the tumor. Specifically, embodiments of the present invention could be applied to a catheter or an endoscope and advanced antegradely or retrogradely to the intended site of local drug delivery. Chemotherapeutic agents that could be effective in this manner include, but are not limited to, microtubule stabilizing agents (e.g. taxanes including paclitaxel and epothilones), topoisomerase I inhibitors (e.g. irinotecan), platinum derivatives (e.g. oxaliplatin, cisplatin, carboplatin), anthracyclines (daunorubicin, epirubicin), 5-FU, and targeted biologic therapies (e.g. anti-VEGF antibodies such as bevacizumab). The advantages of this method are that high doses of effective chemotherapeutic agents can be delivered to the tumor without systemic toxicity, the patient's diet would not have to be modified to prevent food impaction, and the mechanical complications of stent placement including indirect tracheal compression, stent migration, and stent occlusion could be avoided. Therapeutic agent for the above indication that exhibit water-only solubility or require water for solubilization such as carboplatin, cisplatin, the epothilones, and targeted proteins such as antibodies (such as the anti-VEGF antibody bevacizumab) can be formulated into the disclosed amphiphilic polymer coating by the use of water as part or all of the solvent.
A similar approach could be used with malignancies of the biliary tract. Cholangiocarcinoma is the most common biliary tract malignancy. It is caused by dysregulated division of cholangiocytes. These tumors can compromise the functional lumen of the intra- or extra-hepatic biliary tree causing cholestasis and consequent cholangitis, pruritis, fat malabsorption, and anorexia.
It is envisioned that an approach to restoring functional luminal patency could be to mechanically restore luminal patency by displacing the tumor with a balloon, blade, or metal dilator or reduce tumor bulk (e.g. laser ablation), and then locally deliver a therapeutic agent to inhibit tumor growth and/or tumor survival utilizing embodiment of the present invention. Chemotherapeutic agents that could be effective in this manner include, but are not limited to, microtubule stabilizing agents (e.g. taxanes including paclitaxel and epothilones), platinum derivatives (e.g. oxaliplatin, cisplatin, carboplatin), anthracyclines (daunorubicin, epirubicin), 5-FU, DNA cross-linkers (mitomycin-C), alkylating nitrosoureas (lomustine), interferons (interferon-alpha), and targeted biologically active agents (e.g. EGFR inhibitors such as cetuximax). The advantages of this method are that high doses of effective chemotherapeutic agents can be delivered to the tumor without systemic toxicity, and the mechanical complications of stent placement including stent migration and stent occlusion could be avoided.
Approaches similar to that described above for esophageal and biliary tract malignancies could be developed for small bowel and colonic malignancies. Analogous approaches could also be used to locally delivery therapeutic agents to non-malignant gastrointestinal diseases (e.g. anti-inflammatory agents delivered to treat inflammatory bowel disease). Therapeutic agents for the above indication that exhibit water-only solubility or require water for solubilization such as carboplatin, cisplatin, the epothilones, interferons (interferon-alpha) and targeted proteins such as antibodies (such as the EGFR inhibitor cetuximab) can be formulated into the disclosed amphiphilic polymer coating by the use of water as part or all of the solvent system.
In the foregoing specification, various embodiments of the invention have been described. It will, however, be evident that various modifications and changes may be made thereto without departing from the broader spirit and scope of the invention as set forth in the appended claims. The specification and drawings are, accordingly, to be regarded in an illustrative sense rather than a restrictive sense
This application is a divisional of U.S. patent application Ser. No. 12/558,420, filed Sep. 11, 2009, which is a continuation-in-part application related to, incorporating by reference and claiming the priority benefit of U.S. patent application Ser. No. 12/210,344, filed Sep. 15, 2008, now U.S. Pat. No. 8,257,722.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4010259 | Johansson | Mar 1977 | A |
| 4589873 | Schwartz et al. | May 1986 | A |
| 4814470 | Colin et al. | Mar 1989 | A |
| 4847324 | Creasy | Jul 1989 | A |
| 4857653 | Colin et al. | Aug 1989 | A |
| 4942184 | Haugwitz et al. | Jul 1990 | A |
| 4950256 | Luther et al. | Aug 1990 | A |
| 5001009 | Whitboume | Mar 1991 | A |
| 5059699 | Kingston et al. | Oct 1991 | A |
| 5200534 | Rao | Apr 1993 | A |
| 5202448 | Carver et al. | Apr 1993 | A |
| 5229529 | Ueno et al. | Jul 1993 | A |
| 5248796 | Chen et al. | Sep 1993 | A |
| 5254580 | Chen et al. | Oct 1993 | A |
| 5256701 | Tamura et al. | Oct 1993 | A |
| 5272171 | Ueda et al. | Dec 1993 | A |
| 5274137 | Nicolaou et al. | Dec 1993 | A |
| 5278324 | Kingston et al. | Jan 1994 | A |
| 5279949 | Nair | Jan 1994 | A |
| 5283253 | Holton et al. | Feb 1994 | A |
| 5294637 | Chen et al. | Mar 1994 | A |
| 5300638 | Farina et al. | Apr 1994 | A |
| 5302392 | Karakelle et al. | Apr 1994 | A |
| 5302394 | Beahm | Apr 1994 | A |
| 5304121 | Sahatjian | Apr 1994 | A |
| 5331027 | Whitbourne | Jul 1994 | A |
| 5350866 | Holton et al. | Sep 1994 | A |
| 5352805 | Kingston et al. | Oct 1994 | A |
| 5362831 | Mongelli et al. | Nov 1994 | A |
| 5380751 | Chen et al. | Jan 1995 | A |
| 5395850 | Roth | Mar 1995 | A |
| 5411984 | Kingston et al. | May 1995 | A |
| 5412092 | Rey et al. | May 1995 | A |
| 5422364 | Nicolaou et al. | Jun 1995 | A |
| 5440056 | Klein et al. | Aug 1995 | A |
| 5464650 | Berg et al. | Nov 1995 | A |
| 5525348 | Whitbourne et al. | Jun 1996 | A |
| 5616608 | Kinsella et al. | Apr 1997 | A |
| 5662609 | Slepian | Sep 1997 | A |
| 5674192 | Sahatjian et al. | Oct 1997 | A |
| 5733888 | Carver et al. | Mar 1998 | A |
| 5733925 | Kunz et al. | Mar 1998 | A |
| 5762638 | Shikani et al. | Jun 1998 | A |
| 5788979 | Alt et al. | Aug 1998 | A |
| 5811447 | Kunz et al. | Sep 1998 | A |
| 5824049 | Ragheb et al. | Oct 1998 | A |
| 5886026 | Hunter et al. | Mar 1999 | A |
| 5900246 | Lambert | May 1999 | A |
| 5954706 | Sahatjian | Sep 1999 | A |
| 5968538 | Snyder, Jr. | Oct 1999 | A |
| 5972992 | Carver et al. | Oct 1999 | A |
| 5977164 | Carver et al. | Nov 1999 | A |
| 6074659 | Kunz et al. | Jun 2000 | A |
| 6096070 | Ragheb et al. | Aug 2000 | A |
| 6096331 | Desai et al. | Aug 2000 | A |
| 6110483 | Whitbourne et al. | Aug 2000 | A |
| 6120784 | Snyder, Jr. | Sep 2000 | A |
| 6146358 | Rowe | Nov 2000 | A |
| 6156373 | Zhong et al. | Dec 2000 | A |
| 6179817 | Zhong | Jan 2001 | B1 |
| 6218016 | Tedeschi et al. | Apr 2001 | B1 |
| 6268390 | Kunz | Jul 2001 | B1 |
| 6299604 | Ragheb et al. | Oct 2001 | B1 |
| 6306166 | Barry | Oct 2001 | B1 |
| 6306421 | Kunz et al. | Oct 2001 | B1 |
| 6369039 | Palasis et al. | Apr 2002 | B1 |
| 6403635 | Kinsella et al. | Jun 2002 | B1 |
| 6419692 | Yang et al. | Jul 2002 | B1 |
| 6429232 | Kinsella et al. | Aug 2002 | B1 |
| 6506408 | Palasis | Jan 2003 | B1 |
| 6506411 | Hunter et al. | Jan 2003 | B2 |
| 6515009 | Kunz et al. | Feb 2003 | B1 |
| 6537579 | Desai et al. | Mar 2003 | B1 |
| 6544544 | Hunter et al. | Apr 2003 | B2 |
| 6638767 | Unger et al. | Oct 2003 | B2 |
| 6638797 | Noguchi et al. | Oct 2003 | B2 |
| 6663881 | Kunz et al. | Dec 2003 | B2 |
| 6673053 | Wang et al. | Jan 2004 | B2 |
| 6730064 | Ragheb et al. | May 2004 | B2 |
| 6753071 | Pacetti | Jun 2004 | B1 |
| 6774278 | Ragheb et al. | Aug 2004 | B1 |
| 6835387 | Herrmann | Dec 2004 | B2 |
| 6846815 | Myers et al. | Jan 2005 | B2 |
| 6855770 | Pinchuk et al. | Feb 2005 | B2 |
| 6918927 | Bates et al. | Jul 2005 | B2 |
| 6926919 | Hossainy et al. | Aug 2005 | B1 |
| 7008979 | Schottman et al. | Mar 2006 | B2 |
| 7105175 | Schwarz | Sep 2006 | B2 |
| 7179251 | Palasis | Feb 2007 | B2 |
| 7279174 | Pacetti et al. | Oct 2007 | B2 |
| 7291165 | Rosenthal et al. | Nov 2007 | B2 |
| 7381418 | Richard | Jun 2008 | B2 |
| 7407507 | Maeda et al. | Aug 2008 | B2 |
| 7445792 | Toner et al. | Nov 2008 | B2 |
| 7482034 | Boulais | Jan 2009 | B2 |
| 7541047 | Rogasch et al. | Jun 2009 | B2 |
| 7750041 | Speck et al. | Jul 2010 | B2 |
| 7803149 | Bates et al. | Sep 2010 | B2 |
| 7811622 | Bates et al. | Oct 2010 | B2 |
| 7875284 | Reyes et al. | Jan 2011 | B2 |
| 7914806 | Strickler et al. | Mar 2011 | B2 |
| 7919108 | Reyes et al. | Apr 2011 | B2 |
| 8021678 | Hossainy et al. | Sep 2011 | B2 |
| 8114429 | Michal et al. | Feb 2012 | B2 |
| 8128951 | Michal et al. | Mar 2012 | B2 |
| 8147540 | Reyes et al. | Apr 2012 | B2 |
| 8257222 | Silveri et al. | Sep 2012 | B2 |
| 8257305 | Speck et al. | Sep 2012 | B2 |
| 8257722 | Michal et al. | Sep 2012 | B2 |
| 8313521 | Ruane et al. | Nov 2012 | B2 |
| 8389043 | Speck et al. | Mar 2013 | B2 |
| 8389049 | Asahi et al. | Mar 2013 | B2 |
| 8439868 | Speck et al. | May 2013 | B2 |
| 8491925 | Michal et al. | Jul 2013 | B2 |
| 9198968 | Michal et al. | Dec 2015 | B2 |
| 20020151844 | Yang et al. | Oct 2002 | A1 |
| 20030052424 | Turner et al. | Mar 2003 | A1 |
| 20030059454 | Barry et al. | Mar 2003 | A1 |
| 20030203991 | Schottman et al. | Oct 2003 | A1 |
| 20030225451 | Sundar | Dec 2003 | A1 |
| 20040073284 | Bates et al. | Apr 2004 | A1 |
| 20040117006 | Lewis et al. | Jun 2004 | A1 |
| 20040117007 | Whitbourne et al. | Jun 2004 | A1 |
| 20040175406 | Schwarz | Sep 2004 | A1 |
| 20040241094 | Chung et al. | Dec 2004 | A1 |
| 20050004661 | Lewis et al. | Jan 2005 | A1 |
| 20050036946 | Pathak et al. | Feb 2005 | A1 |
| 20050059965 | Eberl et al. | Mar 2005 | A1 |
| 20050147690 | Masters et al. | Jul 2005 | A1 |
| 20050159704 | Scott et al. | Jul 2005 | A1 |
| 20050226903 | Rogasch et al. | Oct 2005 | A1 |
| 20050250672 | Speck et al. | Nov 2005 | A9 |
| 20050251250 | Verhoeven | Nov 2005 | A1 |
| 20050278021 | Bates et al. | Dec 2005 | A1 |
| 20060020243 | Speck et al. | Jan 2006 | A1 |
| 20060020331 | Bates et al. | Jan 2006 | A1 |
| 20060034769 | Kohn et al. | Feb 2006 | A1 |
| 20060212106 | Weber et al. | Sep 2006 | A1 |
| 20060228453 | Cromack et al. | Oct 2006 | A1 |
| 20060240070 | Cromack et al. | Oct 2006 | A1 |
| 20070065481 | Chudzik et al. | Mar 2007 | A1 |
| 20070065482 | Chudzik et al. | Mar 2007 | A1 |
| 20070065483 | Chudzik et al. | Mar 2007 | A1 |
| 20070065484 | Chudzik et al. | Mar 2007 | A1 |
| 20070071792 | Varner et al. | Mar 2007 | A1 |
| 20070078446 | Lavelle | Apr 2007 | A1 |
| 20070104766 | Wang et al. | May 2007 | A1 |
| 20070190103 | Hossainy et al. | Aug 2007 | A1 |
| 20080020013 | Reyes et al. | Jan 2008 | A1 |
| 20080021385 | Barry et al. | Jan 2008 | A1 |
| 20080051871 | Tuch | Feb 2008 | A1 |
| 20080078400 | Martens et al. | Apr 2008 | A1 |
| 20080102033 | Speck et al. | May 2008 | A1 |
| 20080102034 | Speck et al. | May 2008 | A1 |
| 20080113035 | Hunter | May 2008 | A1 |
| 20080118543 | Pacetti et al. | May 2008 | A1 |
| 20080118544 | Wang | May 2008 | A1 |
| 20080124372 | Hossainy et al. | May 2008 | A1 |
| 20080132992 | Bates et al. | Jun 2008 | A1 |
| 20080140002 | Ramzipoor et al. | Jun 2008 | A1 |
| 20080145396 | Bates et al. | Jun 2008 | A1 |
| 20080146489 | Pacetti et al. | Jun 2008 | A1 |
| 20080153900 | Hunter | Jun 2008 | A1 |
| 20080175887 | Wang | Jul 2008 | A1 |
| 20080286325 | Reyes et al. | Nov 2008 | A1 |
| 20080311173 | Schwarz et al. | Dec 2008 | A1 |
| 20090054837 | Von Holst et al. | Feb 2009 | A1 |
| 20090074707 | Rogasch et al. | Mar 2009 | A1 |
| 20090098176 | Helmus et al. | Apr 2009 | A1 |
| 20090112239 | To | Apr 2009 | A1 |
| 20090136560 | Bates et al. | May 2009 | A1 |
| 20090186414 | Srivastava et al. | Jul 2009 | A1 |
| 20090196931 | Kunz et al. | Aug 2009 | A1 |
| 20090216317 | Cromack et al. | Aug 2009 | A1 |
| 20090218731 | Rogasch et al. | Sep 2009 | A1 |
| 20090227948 | Chen et al. | Sep 2009 | A1 |
| 20090227949 | Knapp et al. | Sep 2009 | A1 |
| 20090285974 | Kerrigan et al. | Nov 2009 | A1 |
| 20090297584 | Lim et al. | Dec 2009 | A1 |
| 20100015200 | McClain et al. | Jan 2010 | A1 |
| 20100030183 | Toner et al. | Feb 2010 | A1 |
| 20100063570 | Pacetti et al. | Mar 2010 | A1 |
| 20100063585 | Hoffmann et al. | Mar 2010 | A1 |
| 20100137975 | Wittchow | Jun 2010 | A1 |
| 20100198190 | Michal et al. | Aug 2010 | A1 |
| 20100233236 | Zhao | Sep 2010 | A1 |
| 20100278744 | Speck et al. | Nov 2010 | A1 |
| 20110015664 | Kangas et al. | Jan 2011 | A1 |
| 20110015725 | Bates et al. | Jan 2011 | A1 |
| 20110070355 | Bavaro et al. | Mar 2011 | A1 |
| 20110143014 | Stankus et al. | Jun 2011 | A1 |
| 20110144577 | Stankus et al. | Jun 2011 | A1 |
| 20110153007 | Reyes et al. | Jun 2011 | A1 |
| 20110196340 | Barry et al. | Aug 2011 | A1 |
| 20110295200 | Speck et al. | Dec 2011 | A1 |
| 20120064141 | Andreacchi et al. | Mar 2012 | A1 |
| 20120064223 | Gamez et al. | Mar 2012 | A1 |
| 20120078228 | Michal et al. | Mar 2012 | A1 |
| 20120135133 | O'Neill et al. | May 2012 | A1 |
| 20120165922 | Gong et al. | Jun 2012 | A1 |
| 20120239001 | Barry et al. | Sep 2012 | A1 |
| 20120289933 | Michal et al. | Nov 2012 | A1 |
| 20130053947 | Kangas et al. | Feb 2013 | A1 |
| 20130129814 | Pacetti et al. | May 2013 | A1 |
| 20130189329 | Wang | Jul 2013 | A1 |
| 20130197436 | Wang | Aug 2013 | A1 |
| Number | Date | Country |
|---|---|---|
| 012091 | Aug 2009 | EA |
| 0681475 | Nov 1995 | EP |
| 0706376 | Apr 1996 | EP |
| 0797988 | Oct 1997 | EP |
| 1011171 | Jun 2000 | EP |
| 1011743 | Jun 2000 | EP |
| 1118325 | Jul 2001 | EP |
| 1372737 | Jan 2004 | EP |
| 1539266 | Jun 2005 | EP |
| 1539267 | Jun 2005 | EP |
| 1632259 | Mar 2006 | EP |
| 1649853 | Apr 2006 | EP |
| 1666070 | Jun 2006 | EP |
| 1666071 | Jun 2006 | EP |
| 1666092 | Jun 2006 | EP |
| 1669092 | Jun 2006 | EP |
| 1857127 | Nov 2007 | EP |
| 1986711 | Nov 2008 | EP |
| 2004251 | Dec 2008 | EP |
| 2010244 | Jan 2009 | EP |
| 2193813 | Jun 2010 | EP |
| 2200674 | Jun 2010 | EP |
| 9112779 | Sep 1991 | WO |
| 9311120 | Jun 1993 | WO |
| 9416706 | Aug 1994 | WO |
| 9503036 | Feb 1995 | WO |
| 9858988 | Dec 1998 | WO |
| 9908729 | Feb 1999 | WO |
| 0128589 | Apr 2001 | WO |
| 2004028610 | Apr 2004 | WO |
| 2005044506 | May 2005 | WO |
| 2006022754 | Mar 2006 | WO |
| 2007035865 | Mar 2007 | WO |
| 2007094940 | Aug 2007 | WO |
| 2007111885 | Oct 2007 | WO |
| 2007112006 | Oct 2007 | WO |
| 2007143159 | Dec 2007 | WO |
| 2008003298 | Jan 2008 | WO |
| 2008031596 | Mar 2008 | WO |
| 2008104573 | Sep 2008 | WO |
| 2009036014 | Mar 2009 | WO |
| 2009124570 | Oct 2009 | WO |
| 2010030995 | Mar 2010 | WO |
| 2011106027 | Sep 2011 | WO |
| Entry |
|---|
| PCT International Search Report and Written Opinion for International Application No. PCT/US2009/056842, dated Dec. 17, 2009, 8 pages. |
| U.S. Appl. No. 12/121,692, filed May 15, 2008, Kerrigan, Cameron K. |
| PCT International Preliminary Report on Patentability for International Application No. PCT/US2009/056842, dated Mar. 15, 2011, 7 pages. |
| PCT International Search Report and Written Opinion for International Application No. PCT/US2010/027731, dated Mar. 21, 2011, 11 pages. |
| Gray, William A., et al., “Drug-Coated Balloons for the Prevention of Vascular Restenosis” Circulation: Journal of the American Heart Association, vol. 121, pp. 2672-2680, accessible at http://circ.ahajournals.org/cgi/content/full/121/24/2672,American Heart Association, Dallas, TX. |
| PCT International Search Report and Written Opinion for International Application No. PCT/US2009/056842, dated Mar. 31, 2010, 17 pages. |
| Katsuda, S., et al., “The Role of Cytoplasmic Microtubules in Regulation of Smooth Muscle Proliferation.” International Atherosclerosis Society Poster Sessions, Abstract Book from 8.sup.th International Symposium on Atherosclerosis, Rome, Oct. 9-13, 1988, p. 446. |
| B. Braun Vascular Systems, “SeQuent.RTM. Please”, Product Brochure No. 6050120, http://www.deb-bbraun.com/doc/doc.sub.--download.cfm?6736&uuid=9- E5F74B02A5AE6266471CF5AF5F43933&&IRACER.sub.--AUTOLINK&&, B. Braun Melsungen AG Vascular Systems, 10pages, Berlin, Germany. |
| CV Ingenuity Office Action for U.S. Appl. No. 12/210,344 dated Nov. 23, 2010. |
| Jones, David S., Poly(.epsilon.-caprolactone) and poly(.epsilon.-caprolactone)-polyvinylpyrrolidone-iodine blends as ureteral biomaterials: characterisation of mechanical and surface properties, degration and resistance to encrustation in vitro.,Biomaterials, vol. 23, pp. 4449-4458, 2002. |
| Weaver, J.V.M., et al., “Stimulus-Responsive Water-Soluble Polymers Based on 2-Hydroxyethyl Methacrylate” Macromolecules, vol. 37 (7), pp. 2395-2403, Mar. 2004. |
| CV Ingenuity Office Action for U.S. Appl. No. 12/210,344 dated Apr. 19, 2011. |
| CV Ingenuity Office Action for U.S. Appl. No. 12/712,134 dated Mar. 31, 2011. |
| CV Ingenuity Office Action for U.S. Appl. No. 12/726,101 dated Mar. 30, 2011. |
| B. Braun Vascular Systems, “SeQuent.RTM. Please”, Product Brochure No. 6050120, accessed Sep. 9, 2009 at http://www.deb-bbraun.com/doc/doc.sub.--download.cfm?6736&uuid=9E5F74B02A-5AE6266471CF5AF5F43933&&IRACER.sub.—AUTOLINK&&, B. Braun MelsungenAG Vascular Systems, 10 pages, Berlin, Germany. |
| Official Action issued in Japanese Application No. 2012-554976 dated Apr. 2, 2014. |
| Official Action issued in Japanese Application No. 2011-527028 dated Dec. 20, 2013. |
| International Search Report from PCT Application No. PCT/US2013/048052 dated Sep. 6, 2013. |
| CV Ingenuity Office Action for U.S. Appl. No. 12/210,344 dated Mar. 19, 2012. |
| CV Ingenuity Notice of Allowance for U.S. Appl. No. 12/210,344 dated Jun. 12, 2012. |
| PCT International Preliminary Report on Patentability for International Application No. PCT/US2010/027731, dated Aug. 28, 2012, 8 pages. |
| Consigny, P. Macke et al., “Local Delivery of an Antiproliferative Drug with Use of Hydrogel-coated Angioplasty Balloons!”, Journal of Vascular and Interventional Radiology, vol. 5, No. 4, pp. 554-560, Jul.-Aug. 1994. |
| Sollott, “Taxol Inhibits Neointimal Smooth Muscle Cell Accumulation after Angioplasty in the Rat”, The Journal of Clinical Investigation, Inc., vol. 95, pp. 1869-1876, Apr. 1995. |
| CV Ingenuity Notice of Allowance for U.S. Appl. No. 12/712,134 dated Oct. 3, 2011. |
| CV Ingenuity Notice of Allowance for U.S. Appl. No. 12/726,101 dated Sep. 29, 2011. |
| Examiner's First Report issued in Australian Application No. 2013280330 dated Dec. 24, 2014. |
| Official Action issued in Japanese Application No. 2012-554976 dated Jan. 8, 2015. |
| First Examination Report dated Apr. 22, 2015 from New Zealand Appl. No. 701765. |
| Russian Office Action, and English language translation, issued in Russial Appl. No. 2014145442 dated Feb. 15, 2016. |
| European Examination Report from Appl. No. EP 10 716 921.1-1462 dated Jan. 24, 2017. |
| European Examination Report issued in Appl. No. EP 09792515.0 dated May 11, 2017. |
| Canadian Office Action issued in Appl. No. CA 2,942,795 dated Oct. 26, 2017 (5 pages). |
| Number | Date | Country | |
|---|---|---|---|
| 20160058916 A1 | Mar 2016 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12558420 | Sep 2009 | US |
| Child | 14935754 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 12210344 | Sep 2008 | US |
| Child | 12558420 | US |
